The market is witnessing an expansion of nutrigenomic testing services offered by various companies. Beyond basic genetic testing kits, specialized services focused on comprehensive nutrigenomic analysis are becoming more prevalent. These services delve deeper into the genetic factors influencing nutrition, providing consumers with a more thorough understanding of their personalized dietary needs. Another notable trend is the integration of gut microbiome analysis into nutrigenomics.
The intricate relationship between the gut microbiota and nutrient metabolism is gaining attention, with companies offering combined genetic and microbiome testing services. This dual approach aims to provide a more holistic understanding of how genetic and microbial factors contribute to individualized nutrition. Moreover, Collaboration between Nutritional genomicsand the food industry is increasing as companies seek to align their product offerings with personalized nutrition trends. This collaboration involves the development of genetically informed food products and supplements designed to cater to specific genetic profiles. Such partnerships aim to create a synergy between the science of Nutritional genomics and the practical implementation of personalized dietary solutions.
There is an increasing number of CVD cases in the United Kingdom. It can help identify genetic factors that may predispose individuals to certain cardiovascular conditions. In accordance with the data from the International Diabetes Federation (IDF), diabetes prevalence (9.2%) and the number of individuals with diabetes (61 million) are expected to increase by 13% in the European region by 2045, according to IDF projections. The region exhibits the highest incidence of type 1 diabetes annually, with 31,000 new cases and the greatest number of children and adolescents affected (295,000). Additionally, at USD 3,086, the region has the second-highest average cost per person with diabetes. Diabetes incurred 189.3 billion USD in expenditures in 2021, representing 19.6% of global expenditures. Hence, rising CVD and diabetes cases in Europe will drive the growth of the regional market.
The Germany market dominated the Europe Nutrigenomics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $104.8 Million by 2030. The UK market is exhibiting a CAGR of 15.4% during (2023 - 2030). Additionally, The France market would experience a CAGR of 17.2% during (2023 - 2030).
Based on Product, the market is segmented into Reagents & Kits, and Services. Based on End User, the market is segmented into Hospitals & Clinics, Online Platforms, and Others. Based on Application, the market is segmented into Obesity, Diabetes, Cardiovascular Diseases, and Cancer Research. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- Genova Diagnostics
- Metagenics, Inc.
- Nutrigenomix Inc.
- Unilever PLC
- The Gene Box
- Cura Integrative Medicine
- Fagron Genomics S.L.U. (GX Sciences Inc.)
- Xcode Life Sciences Private Limited
- DNA Life
- BASF SE
Market Report Segmentation
By Product- Reagents & Kits
- Services
- Hospitals & Clinics
- Online Platforms
- Others
- Obesity
- Diabetes
- Cardiovascular Diseases
- Cancer Research
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Companies Mentioned
- Genova Diagnostics
- Metagenics, Inc.
- Nutrigenomix Inc.
- Unilever PLC
- The Gene Box
- Cura Integrative Medicine
- Fagron Genomics S.L.U. (GX Sciences Inc.)
- Xcode Life Sciences Private Limited
- DNA Life
- BASF SE
Methodology
LOADING...